TY - JOUR
T1 - Quantification of [18F]florbetapir
T2 - A test–retest tracer kinetic modelling study
AU - Golla, Sandeep S. V.
AU - Verfaillie, Sander C. J.
AU - Boellaard, Ronald
AU - Adriaanse, Sofie M.
AU - Zwan, Marissa D.
AU - Schuit, Robert C.
AU - Timmers, Tessa
AU - Groot, Colin
AU - Schober, Patrick
AU - Scheltens, Philip
AU - van der Flier, Wiesje M.
AU - Windhorst, Albert D.
AU - van Berckel, Bart N. M.
AU - Lammertsma, Adriaan A.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Accumulation of amyloid beta can be visualized using [18F]florbetapir positron emission tomography. The aim of this study was to identify the optimal model for quantifying [18F]florbetapir uptake and to assess test–retest reliability of corresponding outcome measures. Eight Alzheimer’s disease patients (age: 67 ± 6 years, Mini-Mental State Examination (MMSE): 23 ± 3) and eight controls (age: 63 ± 4 years, MMSE: 30 ± 0) were included. Ninety-minute dynamic positron emission tomography scans, together with arterial blood sampling, were acquired immediately following a bolus injection of 294 ± 32 MBq [18F]florbetapir. Several plasma input models and the simplified reference tissue model (SRTM) were evaluated. The Akaike information criterion was used to identify the preferred kinetic model. Compared to controls, Alzheimer’s disease patients had lower MMSE scores and evidence for cortical Aβ pathology. A reversible two-tissue compartment model with fitted blood volume fraction (2T4k_VB) was the preferred model for describing [18F]florbetapir kinetics. SRTM-derived non-displaceable binding potential (BPND) correlated well (r2= 0.83, slope = 0.86) with plasma input-derived distribution volume ratio. Test–retest reliability for plasma input-derived distribution volume ratio, SRTM-derived BPND and SUVr(50–70) were r = 0.88, r = 0.91 and r = 0.86, respectively. In vivo kinetics of [18F]florbetapir could best be described by a reversible two-tissue compartmental model and [18F]florbetapir BPND can be reliably estimated using an SRTM.
AB - Accumulation of amyloid beta can be visualized using [18F]florbetapir positron emission tomography. The aim of this study was to identify the optimal model for quantifying [18F]florbetapir uptake and to assess test–retest reliability of corresponding outcome measures. Eight Alzheimer’s disease patients (age: 67 ± 6 years, Mini-Mental State Examination (MMSE): 23 ± 3) and eight controls (age: 63 ± 4 years, MMSE: 30 ± 0) were included. Ninety-minute dynamic positron emission tomography scans, together with arterial blood sampling, were acquired immediately following a bolus injection of 294 ± 32 MBq [18F]florbetapir. Several plasma input models and the simplified reference tissue model (SRTM) were evaluated. The Akaike information criterion was used to identify the preferred kinetic model. Compared to controls, Alzheimer’s disease patients had lower MMSE scores and evidence for cortical Aβ pathology. A reversible two-tissue compartment model with fitted blood volume fraction (2T4k_VB) was the preferred model for describing [18F]florbetapir kinetics. SRTM-derived non-displaceable binding potential (BPND) correlated well (r2= 0.83, slope = 0.86) with plasma input-derived distribution volume ratio. Test–retest reliability for plasma input-derived distribution volume ratio, SRTM-derived BPND and SUVr(50–70) were r = 0.88, r = 0.91 and r = 0.86, respectively. In vivo kinetics of [18F]florbetapir could best be described by a reversible two-tissue compartmental model and [18F]florbetapir BPND can be reliably estimated using an SRTM.
KW - Alzheimer’s disease
KW - Amyloid positron emission tomography
KW - [18F]florbetapir
KW - test–retest
KW - tracer kinetic modelling
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049004477&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29897009
UR - http://www.scopus.com/inward/record.url?scp=85049004477&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/0271678X18783628
DO - https://doi.org/10.1177/0271678X18783628
M3 - Article
C2 - 29897009
SN - 0271-678X
VL - 39
SP - 2172
EP - 2180
JO - Journal of cerebral blood flow and metabolism
JF - Journal of cerebral blood flow and metabolism
IS - 11
ER -